ストックスクリーナーアプリを入手
51.75
1.02%
0.52
アフターアワーズ：
51.75
前日終値:
$51.23
開ける：
$48.91
24時間の取引高:
244.52K
Relative Volume:
0.52
時価総額：
$3.54B
収益：
$38.34M
当期純損益:
$-149.65M
株価収益率:
-13.76
EPS:
-3.76
ネットキャッシュフロー:
$-150.28M
1週間 パフォーマンス:
-0.33%
1か月 パフォーマンス:
-0.06%
6か月 パフォーマンス:
+7.01%
1年 パフォーマンス:
+108.00%
1日の値動き範囲:
$48.42
$51.95
1週間の範囲:
$48.42
$52.39
52週間の値動き範囲:
$22.01
$61.61
Merus N V Stock (MRUS) Company Profile
Merus N V Stock (MRUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-02 | 開始されました | Canaccord Genuity | Buy |
| 2023-08-21 | 開始されました | TD Cowen | Outperform |
| 2022-08-02 | 開始されました | Stifel | Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Needham | Buy |
| 2021-11-17 | 再開されました | Guggenheim | Buy |
| 2021-06-07 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-08 | 開始されました | William Blair | Outperform |
| 2021-03-16 | 開始されました | SVB Leerink | Outperform |
| 2020-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 再開されました | Guggenheim | Buy |
| 2019-06-28 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 再開されました | Guggenheim | Buy |
| 2019-04-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 開始されました | Berenberg | Buy |
| 2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-03-21 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-12-22 | アップグレード | Citigroup | Neutral → Buy |
| 2016-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-06-13 | 開始されました | Citigroup | Buy |
| 2016-06-13 | 開始されました | Guggenheim | Buy |
| 2016-06-13 | 開始されました | Wedbush | Outperform |
すべてを表示
Merus N V (MRUS) 最新ニュース
FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com UK
Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat
Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha
US FDA extends review of Merus' gene-targeting cancer therapy - Reuters
US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive
Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno - Investing.com
Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire
Harbor Capital Advisors Inc. Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
abrdn plc Acquires Shares of 87,215 Merus (NASDAQ:MRUS) - MarketBeat
Merus sees cash runway into 2028 - MSN
Merus reports Q3 EPS ($1.46), consensus (88c) - MSN
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Merus N.V. Reports Q3 2024 Financial Results - TipRanks
Merus falls after updated data for lung cancer therapy - MSN
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India
Moody Aldrich Partners LLC Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment By Investing.com - Investing.com South Africa
Merus (NASDAQ:MRUS) Receives New Coverage from Analysts at UBS Group - MarketBeat
(MRUS) Investment Report - Stock Traders Daily
nVerses Capital LLC Acquires 1,500 Shares of Merus (NASDAQ:MRUS) - Defense World
Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain - Yahoo Finance
Analysts Set Merus (NASDAQ:MRUS) Target Price at $82.00 - Defense World
Market Resilience: Merus N.V (MRUS) Finishes Weak at 51.35, Down -1.57 - The Dwinnex
Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews
A company insider recently sold 2,500 shares of Merus N.V [MRUS]. Should You also Consider to Sale? - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: Merus N.V (MRUS) - SETE News
Merus (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
VP Controller, PAO Shuman Harry sale 2,500 shares of Merus N.V [MRUS] - Knox Daily
Market Highlights: Merus N.V (MRUS) Ends on a Low Note at 52.09 - The Dwinnex
There is no way Merus N.V (MRUS) can keep these numbers up - SETE News
What is the investor’s view on Merus N.V (MRUS)? - US Post News
Merus N.V (MRUS) receives a Buy rating from Truist - Knox Daily
Merus (NASDAQ:MRUS) Holdings Lowered by The Manufacturers Life Insurance Company - Defense World
Millennium Management LLC Has $14.39 Million Stock Position in Merus (NASDAQ:MRUS) - MarketBeat
Prepare Yourself for Liftoff: Merus N.V (MRUS) - SETE News
Guggenheim Raises Merus (NASDAQ:MRUS) Price Target to $111.00 - MarketBeat
Checking in on Merus N.V (MRUS) after recent insiders movement - Knox Daily
Merus (NASDAQ:MRUS) Price Target Raised to $111.00 at Guggenheim - Defense World
Merus NV: Driving Innovation in Cancer Treatment with Shares Valued at $50.33 - NasdaqNewsFeed
Merus begins phase 3 trial for head and neck cancer therapy - Investing.com Canada
Merus (NASDAQ:MRUS) Shares Up 4.7% - Defense World
Merus's SWOT analysis: bispecific antibody developer's stock shows promise - Investing.com India
BMO maintains Merus $95 target on positive trial data By Investing.com - Investing.com Canada
Merus begins phase 3 trial for head and neck cancer therapy By Investing.com - Investing.com South Africa
Merus's SWOT analysis: bispecific antibody developer's stock shows promise By Investing.com - Investing.com Australia
Merus N V (MRUS) 財務データ
収益
当期純利益
現金流量
EPS
Merus N V (MRUS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 10 '24 |
Sale |
53.22 |
1,000 |
53,224 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 04 '24 |
Sale |
52.89 |
6,000 |
317,354 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Dec 19 '23 |
Sale |
26.68 |
115 |
3,068 |
7,002 |
| Silverman Peter B. | COO & GC |
Dec 15 '23 |
Sale |
25.00 |
22,386 |
559,650 |
0 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):